$251 Million is the total value of COMMODORE CAPITAL LP's 31 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 39.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $25,908,000 | +199.7% | 1,028,084 | -23.1% | 10.32% | +119.5% |
| CCCC | C4 THERAPEUTICS INC | $17,795,000 | +11.6% | 481,094 | 0.0% | 7.09% | -18.2% | |
| KURA | Buy | KURA ONCOLOGY INC | $14,744,000 | +238.2% | 521,555 | +290.7% | 5.87% | +147.8% |
| STSA | New | SATSUMA PHARMACEUTICALS INC | $14,371,000 | – | 2,431,705 | +100.0% | 5.72% | – |
| FPRX | Sell | FIVE PRIME THERAPEUTICS INC | $13,612,000 | +50.4% | 361,344 | -32.1% | 5.42% | +10.2% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $13,545,000 | +58.8% | 2,983,513 | +100.8% | 5.40% | +16.3% |
| COGT | Buy | COGENT BIOSCIENCES INC | $11,144,000 | +30.6% | 1,269,195 | +67.0% | 4.44% | -4.3% |
| ISEE | Buy | IVERIC BIO INC | $10,685,000 | +21.4% | 1,729,041 | +35.7% | 4.26% | -11.1% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $9,055,000 | +29.2% | 349,600 | +0.6% | 3.61% | -5.3% |
| KRON | KRONOS BIO INC | $8,747,000 | -2.0% | 298,839 | 0.0% | 3.48% | -28.2% | |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $8,618,000 | -29.4% | 368,448 | -13.0% | 3.43% | -48.3% |
| Sell | TRILLIUM THERAPEUTICS INC | $8,548,000 | -31.9% | 795,868 | -6.7% | 3.40% | -50.1% | |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $7,944,000 | +30.0% | 3,729,694 | +18.4% | 3.16% | -4.7% |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $7,782,000 | +82.1% | 2,871,624 | +62.6% | 3.10% | +33.4% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $7,621,000 | +22.0% | 369,951 | +3.8% | 3.04% | -10.6% |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $6,945,000 | +64.3% | 429,228 | +170.2% | 2.77% | +20.4% |
| MREO | Buy | MEREO BIOPHARMA GROUP PLCads | $6,904,000 | +4.0% | 2,048,757 | +10.5% | 2.75% | -23.8% |
| DYN | New | DYNE THERAPEUTICS INC | $6,680,000 | – | 430,112 | +100.0% | 2.66% | – |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $5,689,000 | -0.7% | 161,565 | -9.5% | 2.27% | -27.2% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $5,510,000 | – | 214,467 | +100.0% | 2.20% | – |
| XENE | Sell | XENON PHARMACEUTICALS INC | $5,395,000 | -24.9% | 301,392 | -35.5% | 2.15% | -45.0% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $5,288,000 | -28.0% | 236,500 | -28.4% | 2.11% | -47.2% |
| EPIX | New | ESSA PHARMA INC | $5,137,000 | – | 176,821 | +100.0% | 2.05% | – |
| SBTX | SILVERBACK THERAPEUTICS INC | $4,238,000 | -5.9% | 97,143 | 0.0% | 1.69% | -31.0% | |
| PMVP | PMV PHARMACEUTICALS INC | $4,111,000 | -46.5% | 125,000 | 0.0% | 1.64% | -60.8% | |
| IVA | Buy | INVENTIVA SAads | $3,861,000 | +15.3% | 262,658 | +13.7% | 1.54% | -15.5% |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $3,104,000 | – | 185,781 | +100.0% | 1.24% | – |
| MCRB | New | SERES THERAPEUTICS INC | $2,909,000 | – | 141,303 | +100.0% | 1.16% | – |
| BLSA | BCLS ACQUISITION CORP | $2,643,000 | -5.1% | 250,000 | 0.0% | 1.05% | -30.4% | |
| MGNX | New | MACROGENICS INC | $1,485,000 | – | 46,630 | +100.0% | 0.59% | – |
| LSAQ | LIFESCI ACQUISITION II CORP | $1,014,000 | -5.0% | 100,000 | 0.0% | 0.40% | -30.3% | |
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -925,000 | -100.0% | -1.08% | – |
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC | $0 | – | -264,690 | -100.0% | -1.12% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -83,782 | -100.0% | -2.10% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -467,796 | -100.0% | -2.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-10-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.